Our study results indicated that TCF7 likely plays a crucial role in the pathogenesis and treatment response of DLBCL, potentially offering a novel therapeutic target or biomarker for this aggressive malignancy. This evidence concerns the gene TCF7 and diffuse large B-cell lymphoma.